Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial.
Resource Type
Report
Authors
Derebail VK; UNC Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: vimal_derebail@med.unc.edu.; Zhu J; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Crawford ML; Laboratory Corporation of America, Burlington, North Carolina.; Garnier JR; Laboratory Corporation of America, Burlington, North Carolina.; Martin KA; Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Evanston, Illinois.; Skinner S; UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Patel T; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Froment A; UNC Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Sketch MR; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Szeto AH; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Patel SM; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Torrice CD; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Tiefenbacher S; Colorado Coagulation, Laboratory Corporation of America, Englewood, Colorado.; Adcock DM; Laboratory Corporation of America, Burlington, North Carolina.; Grant RP; Laboratory Corporation of America, Burlington, North Carolina.; Key NS; UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Crona DJ; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Pharmacy, UNC Medical Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: daniel.crona@unc.edu.
Source
Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8110075 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6838 (Electronic) Linking ISSN: 02726386 NLM ISO Abbreviation: Am J Kidney Dis Subsets: MEDLINE